Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial | Zendy

Jennifer A. Huntington | Zendy; George Sakoulas | Zendy; Obiamiwe Umeh | Zendy; Daniel Cloutier | Zendy; Judith N. Steenbergen | Zendy; Caleb Bliss | Zendy; Ellie J. C. Goldstein | Zendy

Open Access

Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial

Author(s) -

Jennifer A. Huntington,

George Sakoulas,

Obiamiwe Umeh,

Daniel Cloutier,

Judith N. Steenbergen,

Caleb Bliss,

Ellie J. C. Goldstein

Publication year - 2016

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkw053

Subject(s) - levofloxacin , medicine , tazobactam , antibiotics , randomized controlled trial , urinary system , cutis , microbiology and biotechnology , antibiotic resistance , dermatology , imipenem , biology

Empirical fluoroquinolone therapy is widely used in treating complicated urinary tract infections (cUTIs), even in areas of high fluoroquinolone resistance. While it is believed that high antibiotic concentrations in urine might be sufficient to overcome and effectively treat infections caused by resistant bacteria, clinical trial data validating this assumption are limited. This post hoc analysis evaluated the efficacy of ceftolozane/tazobactam versus levofloxacin in the subgroup of patients with cUTIs caused by levofloxacin-resistant pathogens in a randomized, controlled trial (NCT01345929/NCT01345955).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research